沙美特罗替卡松对以胸痛首发的支气管哮喘FeNO影响的临床研究

Effect of Salmeterol and Fluticasone on FeNO in Bronchial Asthma Patients with Chest Pain

目的分析沙美特罗替卡松粉吸入剂对以胸痛首发的支气管哮喘患者呼出气一氧化氮(Fractional exhald nitric oxide,FeNO)的影响。方法选取2017年1月-2017年6月确诊的以胸痛为首发症状的80例支气管哮喘患者,随机分为观察组(n=40)和对照组(n=40),观察组给予沙美特罗卡松吸入治疗,对照组给予安慰剂治疗。监测观察组与对照组治疗前、1个月、3个月、6个月FeNo水平。结果以胸痛首发的支气管哮喘的Fe NO水平显著高于正常人,经沙美特罗替卡松吸入治疗后,观察组Fe NO水平显著降低,观察组与对照组Fe NO水平分别在1个月、3个月、6个月有统计学意义(P<0.05)。结论吸入沙美特罗替卡松能够改善改善患者胸痛等症状,降低患者FeNO水平。

Objective To analyze the effect of Salmeterol and Fluticasone on Fe NO in bronchial asthma patients with chest pain.Methods 80 patients with bronchial asthma with chest pain diagnosed in our hospital from January 2017 to June 2017 were randomly divided into Observation Group（ n = 40） and Control Group（ n = 40）. The Observation Group was given the treatment of Salmeterol and Fluticasone,and the Control Group was treated with placebo.The Fe No level was detected in the two groups before treatment,1 month,3 months and 6 months after treatment.Results The Fe No level of bronchial asthma patients with chest pain was significantly higher than that of the normal people. After the treatment of Salmeterol and Fluticasone,the Fe No level of the Observation Group was significantly reduced.The Fe No level of the two groups was statistically significant 1 month,3 months and 6 months after treatment（ P〈 0.05）.Conclusion The Salmeterol and Fluticasone can improve symptoms of chest pain and reduce Fe NO level in patients.